Mylan Knocks Ranbaxy's Exclusivity Right For Valsartan
Mylan Pharmaceuticals Inc. on Tuesday hit the U.S. Food and Drug Administration with a lawsuit objecting to its award of a 180-day exclusivity period to Ranbaxy Pharmaceuticals Inc. for the marketing...To view the full article, register now.
Already a subscriber? Click here to view full article